Aquestive Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Aquestive Therapeutics (AQST) with an Overweight rating and $17 price target Th company’s “secret sauce” is developing products with its oral film technology PharmFilm, which can deliver APIs via buccal, sublingual or lingual delivery, the analyst tells investors in a research note. The firm says this same technology is also being used to develop Anaphylm, and epinephrine sublingual film, for the treatment of Type 1 allergic reactions, including anaphylaxis. Following a recent positive meeting with the FDA, Aquestive intends to submit a new drug application in Q1, making this is an “optimal time for investors to re-engage with the story.”